Pronto to Distribute Signal's Myeloma Test | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Myeloma Health's parent company Signal Genetics said today that Pronto Diagnostics will distribute the Signal Myeloma Prognostic Risk Signature (MyPRS) test in Israel, under an exclusive agreement.

Tel Aviv-based Pronto provides molecular diagnostics-based oncology disease tests and genetic test kits, and it serves as a distributor for Pathwork Diagnostics and Epigenomics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.